Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytosorbents (CTSO) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Cytosorbents (CTSO) over the last 9 years, with Q3 2025 value amounting to $62.8 million.

  • Cytosorbents' Shares Outstanding (Diluted Average) rose 1524.43% to $62.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.8 million, marking a year-over-year increase of 1524.43%. This contributed to the annual value of $54.4 million for FY2024, which is 2189.66% up from last year.
  • Cytosorbents' Shares Outstanding (Diluted Average) amounted to $62.8 million in Q3 2025, which was up 1524.43% from $67.2 million recorded in Q2 2025.
  • Over the past 5 years, Cytosorbents' Shares Outstanding (Diluted Average) peaked at $67.2 million during Q2 2025, and registered a low of $43.3 million during Q2 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $49.1 million, with a median of $44.0 million in 2023.
  • As far as peak fluctuations go, Cytosorbents' Shares Outstanding (Diluted Average) surged by 38.88% in 2022, and later surged by 2463.15% in 2024.
  • Cytosorbents' Shares Outstanding (Diluted Average) (Quarter) stood at $43.4 million in 2021, then increased by 0.49% to $43.6 million in 2022, then grew by 2.49% to $44.7 million in 2023, then increased by 21.9% to $54.4 million in 2024, then increased by 15.28% to $62.8 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $62.8 million for Q3 2025, versus $67.2 million for Q2 2025 and $60.7 million for Q1 2025.